Additional Clinical Programs News Today

Immunocore Holdings Limited: Immunocore Reports First Quarter 2021 Financial Results Launched includes $287 million in net proceeds from initial public offering and concurrent private placement in February 2021 Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced its results ...